PRESS RELEASE 2025

With two in five employees undergoing fertility treatment leaving their jobs or considering quitting, are companies doing enough?

By celia in PRESS RELEASE 2025 on 26 November 2025

With two in five employees undergoing fertility treatment leaving their jobs or…

Ferring Pharmaceuticals to explore strategic options for Rebyota®

By celia in PRESS RELEASE 2025 on 29 October 2025

Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec

By celia in PRESS RELEASE 2025 on 11 September 2025

Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of individualised vs.conventional recombinant follicular stimulating hormone dosing in Indian infertile patients

By celia in PRESS RELEASE 2025 on 03 May 2025

Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of…

U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)

By siddhant in PRESS RELEASE 2025 on 24 April 2025

U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)…

Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC patients

By celia in PRESS RELEASE 2025 on 21 April 2025

Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating…

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin

By celia in PRESS RELEASE 2025 on 09 April 2025

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence…